---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-004350"
form_type: "8-K"
ticker: "PAVM"
cik: "0001624326"
company_name: "PAVmed Inc."
filed_at: "2024-01-30T23:59:59+00:00"
generated_at: "2026-06-06T15:02:35.243571+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# PAVmed elects stock payment of $4.7M fees from Lucid Diagnostics

## Summary
- PAVmed received $4,675,256 of fees/reimbursements from Lucid Diagnostics via 3,331,771 shares of Lucid common stock.
- Lucid Diagnostics is a majority-owned subsidiary of PAVmed.
- Transaction described in more detail in Lucid Diagnostics' Form 8-K filed January 30, 2024.

## SEC filing metadata
- accession: 0001493152-24-004350
- form_type: 8-K
- ticker: PAVM
- cik: 0001624326
- company_name: PAVmed Inc.
- filed_at: 2024-01-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1624326/000149315224004350/0001493152-24-004350-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1624326/000149315224004350/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-004350
- JSON: https://secwatch.observer/filing/0001493152-24-004350.json
- Plain text: https://secwatch.observer/filing/0001493152-24-004350.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.